MILFORD, Mass., April 18, 2012 /PRNewswire/ -- SeraCare Life
Sciences, Inc. (NASDAQ: SRLS), a global life sciences company
providing vital products and services to facilitate the discovery,
development and production of human diagnostics and therapeutics,
announced that, at a special meeting of shareholders held today,
its shareholders voted to adopt the merger agreement with Project
Plasma Holdings Corporation and Project Plasma Merger Corp.,
affiliates of Linden Capital Partners. Linden Capital Partners is a
Chicago-based private equity firm
that focuses on middle market leveraged buyout investments in the
healthcare and life science industries.
(Logo:
http://photos.prnewswire.com/prnh/20110324/NE70714LOGO )
Under the terms of the merger agreement, holders of outstanding
shares of common stock of SeraCare will receive $4.00 per share. The transaction is expected to
close on Friday, April 20, 2012 after
the close of business, subject to the satisfaction of customary
closing conditions. In addition, shareholders also voted to approve
certain compensation arrangements for SeraCare's named executive
officers in connection with the merger.
About Linden Capital Partners:
Linden is a Chicago-based
private equity firm focused exclusively on leveraged buyouts in the
healthcare and life science industries. Linden's investment
strategy is based upon three elements: i) healthcare and life
science industry specialization, ii) integrated private equity and
operating expertise, and iii) strategic relationships with large
corporations. Linden has advised SeraCare that it currently manages
$575 million in capital. For
additional information, please visit www.lindenllc.com.
About SeraCare Life Sciences, Inc.:
SeraCare serves the global life sciences industry by providing
vital products and services to facilitate the discovery,
development and production of human diagnostics and therapeutics.
The Company's innovative portfolio includes diagnostic controls,
plasma-derived reagents and molecular biomarkers, biobanking and
contract research services. SeraCare's quality systems, scientific
expertise and state-of-the-art facilities support its customers in
meeting the stringent requirements of the highly regulated life
sciences industry. For additional information, please visit
www.seracare.com.
Forward-Looking Statements:
This press release contains disclosures that are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 about SeraCare Life Sciences, Inc. ("SeraCare"
or the "Company") and the proposed merger. Forward-looking
statements include statements in which we use words such as
"expect," "believe," "anticipate," "intend," or similar
expressions. These forward-looking statements are based upon
information presently available to the Company's management and are
inherently subjective, uncertain and subject to change, due to any
number of risks and uncertainties. Factors that could cause
events not to occur as expressed in the forward-looking statements
in this press release include, but are not limited to,
unanticipated delays; the occurrence of any event, change or other
circumstances that could give rise to the termination of the merger
agreement; the outcome of any legal proceedings that may be
instituted with respect to the proposed merger; and the inability
to complete the merger due to the failure to satisfy closing
conditions, as well as other risk factors detailed in the Company's
Annual Report on Form 10-K filed with the SEC on November 21, 2011, as amended, under the captions
"Cautionary Note Regarding Forward-Looking Statements" and "Risk
Factors" and otherwise in the Company's reports and filings with
the Securities and Exchange Commission. Many of these factors are
beyond our ability to control or predict. You should not place
undue reliance on any forward-looking statements, since those
statements speak only as of the date that they are made. SeraCare
assumes no obligation to update, revise or correct any
forward-looking statements after the date of this press release or
after the respective dates on which such statements otherwise are
made, whether as a result of new information, future events or
otherwise, except as otherwise may be required by law.
Contacts:
For SeraCare Life Sciences:
Gregory A. Gould
Interim President and Chief Executive Officer and Chief Financial
Officer
SeraCare Life Sciences, Inc.
508-244-6400
Sarah Cavanaugh
MacDougall Biomedical Communications
781-235-3060
For Linden Capital Partners:
Brian C. Miller
Managing Partner
Linden Capital Partners
312-506-5600
SOURCE SeraCare Life Sciences, Inc.